Colleen Miller, NP
Gerontology · Eastpointe, MINPI 1285161430
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 178 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 23.1% — the pattern of someone who eats at a lot of different presentations.
Across 178 payments — averaging $16.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$667
- Abbott$431
- AstraZeneca$360
- Lilly USA, LLC$187
- Pfizer$186
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$185
- plus $865 from 17 others
What the payments were for
- Food & beverage$2,880100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 41 | $667 |
| Abbott | 52 | $431 |
| AstraZeneca | 10 | $360 |
| Lilly USA, LLC | 10 | $187 |
| Pfizer | 11 | $186 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 11 | $185 |
| GSK | 9 | $149 |
| Sanofi-aventis U.S. LLC | 1 | $125 |
| Exact Sciences | 6 | $122 |
| AbbVie | 5 | $98 |
| Novartis | 5 | $79 |
| Bayer | 4 | $64 |
| Xeris Pharmaceuticals, Inc. | 3 | $37 |
| Boston Scientific | 1 | $31 |
| Scynexis, Inc. | 1 | $27 |
| Phathom Pharmaceuticals, Inc. | 1 | $20 |
| Sanofi Pasteur Inc. | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Ultragenyx Pharmaceutical Inc. | 1 | $16 |
| OWP Pharmaceuticals, Inc. | 1 | $16 |
| Avanir Pharmaceuticals, Inc. | 1 | $15 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SOLIQUA 100/33$125
- FREESTYLE LIBRE 3$111
- BREZTRI$107
How this compares
$2,880 in reported general payments places this provider in the 85th percentile of 279 gerontology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 75 | $81,347 |
| EliquisApixaban | 76 | $68,998 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 70 | $60,642 |
| OzempicSemaglutide | 52 | $58,258 |
| JardianceEmpagliflozin | 49 | $52,245 |
| JanuviaSitagliptin Phosphate | 38 | $48,946 |
| EntrestoSacubitril/Valsartan | 29 | $23,214 |
| FarxigaDapagliflozin Propanediol | 14 | $18,159 |
| XareltoRivaroxaban | 19 | $17,234 |
| QuliptaAtogepant | 14 | $15,047 |
| Breo ElliptaFluticasone/Vilanterol | 33 | $14,184 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $13,779 |
| Oxymorphone Hcl ErOxymorphone Hcl | 13 | $8,220 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 47 | $6,589 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 14 | $6,537 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $149 | $87,602134 claims |
| Lilly USA, LLCTrulicity | $187 | $81,34775 claims |
| PfizerEliquis | $186 | $68,99876 claims |
| Novo NordiskOzempic | $667 | $58,25852 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $360 | $37,84050 claims |
| NovartisEntresto | $79 | $23,21429 claims |
| AbbVieQulipta | $98 | $15,04714 claims |
| Sanofi-aventis U.S. LLCLantus | $125 | $4,14519 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 279 gerontology providers in Michigan.
Other gerontology in Eastpointe
- Gwendolyn WrightGrand Blanc$47K
- Matthew AmanRochester Hills$21K
- Sarah ArnkoffWest Bloomfield$18K
- Deborah GriffinPetoskey$11K
- Angela EmbreeGrand Rapids$10K
- Bethany DalessandroWyandotte$10K
- Gabrielle NadeauJackson$10K
- Cynthera McNeillWest Bloomfield$9K
- Samantha BurgessGrand Rapids$9K
- Joanna HernandezWarren$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.